Vitrolife introduces EmbryoScope+ and broadens time-lapse portfolio
Vitrolife is the market leader of time-lapse systems for use in assisted reproduction. With the introduction of EmbryoScope+, the company can offer an additional high quality time-lapse system for undisturbed culture and improved selection of embryos. EmbryoScope+ has a l arge capacity in combination with a small footprint, providing an efficient workflow and optimised usage of clinic resources. The product will be introduced at the upcoming ESHRE conference next week in Helsinki, Finland.
EmbryoScope+ is a time-lapse system with an integrated incubator. EmbryoScope+ builds on the same technology as the company´s world-wide used EmbryoScope, but with a larger capacity for 15 patients with up to 16 embryos per patient in a single instrument. The new system has a small footprint, which is an advantage for labs where space is limited.
“The time-lapse market is growing and we believe that time-lapse has the potential to become a standard tool in IVF treatments. With the introduction of EmbryoScope+, we will make our time-lapse offer even more flexible”, says Thomas Axelsson, CEO at Vitrolife.
Time-lapse technology enables the entire development of the embryo to be studied, increasing the probability of choosing the embryo with the best chances of leading to pregnancy. The use of time-lapse technology has been documented to improve clinical outcomes.
Gothenburg, June 27, 2016
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on June 27, 2016 at 08:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 360 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary, Denmark and Germany. The Vitrolife share is listed on NASDAQ Stockholm, Mid Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: email@example.com. Website: www.vitrolife.com/